Dr. Fruchtman Is a Hematologist/Oncologist With a Proven Track
Record in Clinical Research
Joins Spectrum From Allos Therapeutics, Where He Led Development of
FOLOTYN(R) For Hematologic and Oncologic
Indica
Feb. 24, 2011 (Business Wire) -- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced the appointment of Steven M. Fruchtman, MD, to the position of Vice President of Clinical Development. Dr. Fruchtman will report directly to George Tidmarsh, MD, PhD, the Company's Chief Scientific Officer and Head of Research and Development Operations, and will provide the strategic planning and leadership necessary for managing the Company's clinical development of belinostat, ZEVALIN® and its other pipeline products.
"We are pleased to announce the appointment of Dr. Fruchtman as our Vice President of Clinical Development," said Rajesh C. Shrotriya, M.D., Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. "Steve comes to us from Allos Therapeutics, where he spearheaded the development of FOLOTYN. He was instrumental in the presentation of the FOLOTYN data to the ODAC panel that recommended and ultimately received FDA approval in relapsed/refractory Peripheral T-Cell Lymphoma. He is a board certified hematologist, and will be intimately involved with the development of belinostat and ZEVALIN in new indications including large B-cell lymphoma."
"I am extremely excited to join Spectrum Pharmaceuticals. Spectrum has a very exciting and diversified lineup of drugs both on the market and in late-stage clinical development," said Dr. Fruchtman. "Belinostat has the potential to be an effective treatment for not only Peripheral T-Cell lymphoma, but several other indications as well. Data from the most recent ASH 2010 Meeting shows ZEVALIN® provides durable remission rates in patients with B-Cell lymphomas. I am looking forward to bringing these potential life saving treatments to cancer patients as quickly as possible."
Dr. Fruchtman comes to Spectrum from Allos Therapeutics, where he led the development of pralatrexate for Hematologic and Oncologic indications. After a successful academic career at Mount Sinai Hospital and Medical School in New York, where he was Chief of the Stem Cell Transplantation Program, and prior to joining Allos, Dr. Fruchtman was Senior Director of US Clinical Development and Medical Affairs for Novartis Pharmaceuticals.